Claritev (CTEV) AI Stock Analysis

• Market Cap: $279.91M
• Dividend Yield: N/A
• Average Volume (3M): 145.67K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.13
• Revenue Growth: 0.89%
• EPS Growth: 78.04%
• Country: US
• Employees: 2,700
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Healthcare Information Services
• EPS (TTM): -4.88
• Shares Outstanding: 16,552,723
• 10 Day Avg. Volume: 170,199
• 30 Day Avg. Volume: 145,670
• PEG Ratio: 0.03
• Price to Book (P/B): -4.04
• Price to Sales (P/S): 0.73
• P/FCF Ratio: -57.23
• Enterprise Value/Market Cap: 17.54
• Enterprise Value/Revenue: 5.09
• Enterprise Value/Gross Profit: 18.42
• Enterprise Value/Ebitda: 10.33
• 1Y Price Target: $29.67
• Price Target Upside: -37.04% Downside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 3
• EPS Forecast (FY): -8.86
• Revenue Forecast (FY): $996.15M

• Rating: 46 Neutral
• Price Target: $16.50 ▼(-64.98% Downside)
• Action: Reiterated Date: 03/04/26
• Date: Action: Reiterated 03/04/26

The score is held down primarily by weak financial performance (ongoing net losses and negative equity) and a strongly bearish technical setup (below key moving averages with negative MACD). These are only partly offset by a relatively positive earnings-call outlook (raised guidance, strong renewals, and pipeline/ACV growth) and operating cash flow resilience.

Positive Factors

Operating cash flow resilience

Claritev’s consistent positive operating cash flow (~$108M–$117M) is a durable internal funding source that supports ongoing operations and strategic investment. Over the next 2–6 months this reduces liquidity risk and underpins the company’s ability to pursue technology and pipeline conversion despite accounting losses.

Pipeline & ACV growth

A 67% year-to-date pipeline expansion and $60M of new ACV expected to convert in 2026 materially improves revenue visibility and booking cadence. This structural growth in contracted backlog supports sustainable top-line expansion and margin leverage as contracts convert over the next several quarters.

Renewals & core business strength

High renewal rates among top clients and multi-line growth (network, analytics, payments) reflect sticky enterprise relationships and diversified revenue streams. This durable customer retention and product breadth reduce churn risk and support predictable recurring revenue over the medium term.

Negative Factors

Negative equity & capital structure risk

Negative shareholders’ equity (~ -$174M) materially weakens the balance sheet and constrains financial flexibility. Even with large debt reduction, negative equity elevates refinancing and covenant risks, limits ability to raise capital on favorable terms, and leaves less buffer for future operating shocks.

Persistent net losses and earnings volatility

Sustained and sizable net losses (≈$284M in 2025) despite positive operating metrics indicate earnings quality issues. Persistent losses erode capital, limit reinvestment capacity, and make consistent profitability uncertain, raising medium-term execution and stakeholder confidence risks.

Negative free cash flow trend

While operating cash flow is positive, recent free cash flow turned modestly negative (~ -$10M to -$12M), constraining the firm’s ability to self-fund capex, buybacks, or faster deleveraging. Persistent negative FCF would necessitate external financing and pressure long-term capital allocation flexibility.

Claritev Business Overview & Revenue Model

Company Description

Claritev Corporation, together with its subsidiaries, provides data analytics and technology-enabled cost management, payment, and revenue integrity solutions to the healthcare industry in the United States. The company offers analytics-based services that reduce medical costs, through data-driven algorithms and insights that detect claims over-charges and negotiate or recommend reimbursement; and network-based services that provide contracted discounts with healthcare providers, as well as outsourced network development and management services. It provides payment and revenue integrity services, such as identifying and removing improper and unnecessary charges paid during the claim, as well as services to identify and help restore and preserve underpaid premium dollars. In addition, the company offers data and decision science services including a suite of solutions that apply modern methods of data science to produce descriptive, predictive, and prescriptive analytics that drive optimized benefit plan design, support decision-making, improve clinical outcomes, and reduce the total cost of care; and business-to-business healthcare payments and other services. It serves national and regional insurance companies, Blue Cross and Blue Shield plans, provider-sponsored and independent health plans, TPAs, self-insured health plans, property and casualty insurers, bill review companies, and other companies involved in the claim adjudication process. The company was formerly known as MultiPlan Corporation and changed its name to Claritev Corporation in February 2025. Claritev Corporation was founded in 1980 and is headquartered in New York, New York.

How the Company Makes Money

Claritev generates revenue through a subscription-based model for its cloud services, charging clients monthly or annually for access to its platforms. Additionally, the company offers consulting services that help organizations implement data analytics solutions, which contributes to a significant portion of its revenue. Key partnerships with major cloud service providers and healthcare institutions also play a crucial role in driving sales and expanding its customer base, further enhancing its revenue streams.

Claritev Financial Statement Overview

Summary

Overall fundamentals remain weak: revenue has been mostly flat, profitability is volatile with a deeply negative net margin in 2025, and the balance sheet is pressured by negative equity despite a sharp reduction in reported debt. Positive operating cash flow is a support, but recent slightly negative free cash flow and earnings instability keep the score low.

Income Statement

Revenue has been essentially flat over the last several years (2025: +1.5% after declines in 2022–2024), indicating limited top-line momentum. Profitability is volatile: 2021 was profitable, but the company returned to sizable losses in 2022–2024 and remained deeply negative in 2025 (net loss of ~$284M, about -29% margin). While 2025 shows positive operating profit and a positive EBITDA margin (~3%), the persistently negative net results and sharp year-to-year swings weigh on overall earnings quality.

Balance Sheet

Leverage and capitalization are key concerns. Debt levels have improved dramatically in 2025 versus 2024 (total debt down from ~$4.54B to ~$35.6M), but shareholders’ equity turned negative in 2025 (about -$174M), which reduces financial flexibility and increases balance-sheet risk. Prior years show elevated leverage (including extremely high debt relative to equity in 2024) and consistently negative returns on equity in most years, underscoring historical pressure on the capital structure despite the recent debt reduction.

Cash Flow

Cash generation from operations has remained positive and relatively steady (2024–2025 operating cash flow ~$108M–$117M), which is a meaningful support versus ongoing accounting losses. However, free cash flow turned slightly negative in 2024 and 2025 (around -$10M to -$12M) after strong positive free cash flow in 2020–2023, and 2025 free cash flow declined sharply versus the prior year. Overall, operating cash flow resilience is a strength, but the recent inability to convert it into positive free cash flow is a notable weakness.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	965.41M	930.62M	961.52M	1.08B	1.12B
Gross Profit	266.58M	691.22M	726.06M	875.62M	942.31M
EBITDA	475.44M	-1.01B	651.93M	158.32M	814.99M
Net Income	-284.28M	-1.65B	-91.70M	-572.91M	102.08M
Balance Sheet
Total Assets	4.89B	5.15B	6.96B	7.37B	8.22B
Cash, Cash Equivalents and Short-Term Investments	16.81M	16.85M	71.55M	334.05M	185.33M
Total Debt	4.63B	4.54B	4.57B	4.78B	4.93B
Total Liabilities	5.06B	5.07B	5.26B	5.58B	5.88B
Stockholders Equity	-173.90M	84.02M	1.71B	1.79B	2.34B
Cash Flow
Free Cash Flow	-12.28M	-10.51M	62.87M	282.63M	320.10M
Operating Cash Flow	117.32M	107.62M	171.72M	372.36M	404.69M
Investing Cash Flow	-121.02M	-118.12M	-249.79M	-104.45M	-228.38M
Financing Cash Flow	2.36M	-41.31M	-180.99M	-115.74M	-114.68M

Claritev Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 47.12
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CTEV, the sentiment is Negative. The current price of 47.12 is above the 20-day moving average (MA) of 20.41, above the 50-day MA of 27.94, and above the 200-day MA of 44.70, indicating a bearish trend. The MACD of -3.59 indicates Positive momentum. The RSI at 39.29 is Neutral, neither overbought nor oversold. The STOCH value of 34.71 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CTEV.

Claritev Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NUTX	80 Outperform	$791.35M	3.12	63.86%	―	236.03%	―
HSTM	71 Outperform	$647.31M	37.76	5.87%	0.52%	3.68%	5.62%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
HCAT	50 Neutral	$121.66M	-2.26	-31.33%	―	4.64%	-17.17%
DH	47 Neutral	$174.23M	-2.20	-47.69%	―	-5.30%	46.01%
CTEV	46 Neutral	$279.91M	-2.47	-646.34%	―	0.89%	78.04%
EVH	46 Neutral	$396.32M	-0.85	-75.47%	―	-16.65%	-71.92%

Claritev Corporate Events

Claritev Posts Turnaround 2025 Results, Issues 2026 Outlook

On February 23, 2026, Claritev Corporation reported fourth-quarter 2025 revenue of $246.6 million and a net loss of $80.6 million, with adjusted EBITDA of $151.3 million and strong improvements in operating cash flow and free cash flow versus the prior year. For full-year 2025, revenue rose 3.7% to $965.4 million, net loss narrowed sharply to $284.3 million from $1.65 billion, and the company processed $179.8 billion in claim charges while identifying $25.0 billion in potential medical cost savings, underscoring its role in healthcare cost containment.

Management characterized 2025 as a pivotal turnaround year marked by renewed top-line growth, record bookings, a corporate rebrand, new solutions and partnerships, and a migrated technology foundation. Looking ahead, Claritev initiated 2026 guidance with revenues of $980 million to $1 billion, modest positive free cash flow, and higher capital expenditures, and its board approved a five-year share repurchase program of up to $75 million, signaling confidence in the company’s financial trajectory and commitment to shareholder value despite ongoing net losses.

The most recent analyst rating on (CTEV) stock is a Hold with a $25.00 price target. To see the full list of analyst forecasts on Claritev stock, see the CTEV Stock Forecast page.

Claritev outlines long-term growth strategy at healthcare conference

On January 15, 2026, Claritev Corporation made an investor slide presentation available in conjunction with its appearance at the J.P. Morgan 44th Annual Healthcare Conference, outlining its long-term vision to enhance transparency and affordability in healthcare and detailing its multi-year growth strategy from 2024 through 2030. The materials highlight both the scale of Claritev’s operations and the market challenges it aims to address—such as escalating medical inflation, rising employer and employee healthcare costs, regulatory complexity, and systemic waste—positioning the company as a key player seeking to leverage its enterprise data platform and broad payer, employer and provider relationships to drive sustained growth and deeper impact across the healthcare ecosystem.

The most recent analyst rating on (CTEV) stock is a Hold with a $30.00 price target. To see the full list of analyst forecasts on Claritev stock, see the CTEV Stock Forecast page.

Claritev Ends Former CEO’s Strategic Advisory Role

Claritev Corporation disclosed a governance update involving its former Chief Executive Officer and Executive Chair, Dale White, who currently serves on the company’s board of directors. On December 23, 2025, the company announced that White will end his role as a strategic advisor effective December 31, 2025, a position he assumed after stepping down as Executive Chair on December 31, 2024; he will remain a director on the board, the company waived its right to require 30 days’ notice for ending the advisory role, and no additional compensation will be paid for that advisory service, signaling a formal conclusion to his transitional duties while preserving his board-level involvement.

The most recent analyst rating on (CTEV) stock is a Hold with a $32.00 price target. To see the full list of analyst forecasts on Claritev stock, see the CTEV Stock Forecast page.